T cell Engager treatment in systemic sclerosis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2908; Pres time: Nov 10, 2026; 04:15 PM - 04:30 PM; Location: W304 A-H; In Person; "In conclusion, blinatumomab-mediated B cell depletion appears to be a safe and highly effective induction strategy in severe SSc, leading to sustained clinical improvement and potential reversal of fibrosis. Larger controlled studies are warranted to confirm these findings and define optimal treatment regimens."
Fibrosis • Immunology • Infectious Disease • Scleroderma • Systemic Sclerosis
|
|
Christina Gebhardt1; Hendrik Schulze-Koops2; Dörner Thomas3; Franziska Szelinski4; Hector Rincon-Arevalo5; Marion Subklewe6; Michael von Bergwelt-Baildon7; Alla Skapenko8; Giulia Magno6; Buecklein Veit6
|